GOINPHARMA: 24/7 Breaking News about pharma, healtcare, chemistry
Tuesday, 16 October 2018 - 19:49

Top stories

News of the week

Bayer considering sale of Animal Health business (€6-7bn)

Werner Baumann, CEO of Germany-based group Bayer, has told in an interview that his company’s management is assessing a sale of the Animal Health division. The segment last year delivered €1.6bn, with a 24% EBITDA. The sale might fetch Bayer…

Approvals

Procedures / New drug and device authorizations / Recommendations

Green light to Bluebird’s gene therapy in Europe

Biotech Bluebird has announced today that EMA has accepted the Marketing Authorization Application (MAA) for its LentiGlobin-based  investigational treatment of adolescents and adults with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype. The authorization reflects the excellent clinical data delivered by…

Companies

Healthcare market news

Allergan sells Rhofade for €65m

US-based Aclaris Therapeutics (Pennsylvania) has acquired global rights to Allergan’s Rhofade. The drug is a cutaneous therapy for the treatment of cutaneous facial erythema, which in 2011 was  included into Allergan’s portfolio following the acquisition of Vicept Therapeutics. (Source: Aclaris)

Chemistry

Market and Technology

Bayer’s legal costs to defend glyphosate products skyrocket

Germany-based Bayer has announced today that its legal costs to protect its herbicides Roundup and Ranger Pro from lawsuits launched in California are significantly increasing. Despite of this, Bayer was enjoined to pay $289m in damages caused by glyphosate herbicides….

M&A

Mergers & Acquisitions

Allergan sells Rhofade for €65m

US-based Aclaris Therapeutics (Pennsylvania) has acquired global rights to Allergan’s Rhofade. The drug is a cutaneous therapy for the treatment of cutaneous facial erythema, which in 2011 was  included into Allergan’s portfolio following the acquisition of Vicept Therapeutics. (Source: Aclaris)

Nutraceuticals

Food supplements

Vitamin D myth starts shaking

The New York Times has published today a long article about the controversial views on vitamin D in the scientific community and its economic implications. One of the most fervent supporters of vitamin D, convinced that it brings high benefit…

Pathology

Latest developments

Novartis introduces therapy arsenal for multiple sclerosis

Novartis has introduced today at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Berlin, data related to a clinical trial assessing Gilenya (fingolimod), an oral therapy for MS, in addition…

Safety

News on Product Safety

FDA issues warning about Intercept’s Ocaliva after 19 patients died

The FDA has officially warned doctors about the risks from Intercept Pharmaceuticals’ Ocaliva (obeticholic acid), after 19 patients on Intercept’s drug, developed to treat PBC (Primary Biliary Cholangitis) had died. The FDA, anyway, has specified that the deaths have occurred…

Trials

Preclinical Trials / Clinical Trials / Epidemiology

Agreement on combo immunotherapy between Bristol-Myers Squibb and Compugen

US-based multinational Bristol-Myers Squibb (BMS) yesterday announced it plans to invest $12m in shares of the Israel-based biotech Compugen, in order to fund the clinical trials of investigational drug COM701, which will be tested in combination with immunotherapy Opdivo. Through…